Indivior PLC Announces Inclusion in S&P SmallCap 600® Index

Indivior PLC announced its inclusion in the S&P SmallCap 600® index, effective December 22, 2025. This inclusion is considered an important milestone that aligns the company's capital markets presence with its U.S. business profile. Indivior remains committed to growing its treatment for opioid use disorder, SUBLOCADE®. The S&P SmallCap 600 Index comprises 600 U.S. equities with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable companies. Indivior Pharmaceuticals focuses on developing medicines for opioid use disorder (OUD), aiming to provide access to evidence-based treatments and manage OUD as a chronic disease.